Open AccessIL-15 enhanced antibody-dependent cellular cytotoxicity mediated by NK cells and macrophages
Author(s) -
Meili Zhang,
Bernard Wen,
Olga M. Antón,
Zhengsheng Yao,
Sigrid Dubois,
Lili Ju,
Noriko Sato,
David J. DiLillo,
Richard N. Bamford,
Jeffrey V. Ravetch,
Thomas A. Waldmann
Publication year - 2018
Publication title -
proceedings of the national academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.011
H-Index - 771
eISSN - 1091-6490
pISSN - 0027-8424
DOI - 10.1073/pnas.1811615115
Subject(s) - antibody dependent cell mediated cytotoxicity , cancer research , immunology , antibody , rituximab , immune system , immunotherapy , monoclonal antibody , alemtuzumab , cytotoxicity , cd20 , effector , cd52 , nk 92 , biology , interleukin 21 , t cell , in vitro , biochemistry
Significance Previously we demonstrated that IL-15 by continuous infusion at 2 μg/kg/d for 10 days induced a 38-fold increase in circulating natural killer (NK) cells and a 358-fold increase in CD56bright NK cells. In the present study we demonstrated that IL-15 enhanced antibody-dependent cellular cytotoxicity (ADCC) of tumor-directed monoclonal antibodies in two systems. Both NK cells and macrophages were required for optimal therapeutic responses. These studies support clinical trials of IL-15 combined with tumor-directed monoclonal antibodies. In translation of this study, a phase I trial of IL-15 combined with alemtuzumab has been opened for patients with adult T cell leukemia (ATL) NCT02689453.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom